S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SGM. Lübbert,P. Wijermans,M. Kicinski,S. Chantepie,W. van der Velden,R. Noppeney,L. Griskevicius,A. Neubauer,M. Crysandt,R. Vrhovac,M. Luppi,S. Fuhrmann,E. Audisio,A. Candoni,O. Legrand,R. Foà,G. Gaidano,D. van Lammeren-Venema,E. F. Posthuma,M. Hoogendoorn, A. Giraut,M. Stevens-Kroef,J. H. Jansen,E. Ammatuna,J.-P. Vilque,R. Wäsch, H. Becker,N. Blijlevens, U. Dührsen,F. Baron,S. Suciu,S. Amadori,A. Venditti,G. HulsHemaSphere（2022）引用 1|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
